These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 21493787)

  • 1. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.
    Schuster DM; Savir-Baruch B; Nieh PT; Master VA; Halkar RK; Rossi PJ; Lewis MM; Nye JA; Yu W; Bowman FD; Goodman MM
    Radiology; 2011 Jun; 259(3):852-61. PubMed ID: 21493787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.
    Schuster DM; Nieh PT; Jani AB; Amzat R; Bowman FD; Halkar RK; Master VA; Nye JA; Odewole OA; Osunkoya AO; Savir-Baruch B; Alaei-Taleghani P; Goodman MM
    J Urol; 2014 May; 191(5):1446-53. PubMed ID: 24144687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.
    Schuster DM; Votaw JR; Nieh PT; Yu W; Nye JA; Master V; Bowman FD; Issa MM; Goodman MM
    J Nucl Med; 2007 Jan; 48(1):56-63. PubMed ID: 17204699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis.
    Ren J; Yuan L; Wen G; Yang J
    Acta Radiol; 2016 Apr; 57(4):487-93. PubMed ID: 25907118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
    Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis.
    Turkbey B; Mena E; Shih J; Pinto PA; Merino MJ; Lindenberg ML; Bernardo M; McKinney YL; Adler S; Owenius R; Choyke PL; Kurdziel KA
    Radiology; 2014 Mar; 270(3):849-56. PubMed ID: 24475804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer.
    Hardie AD; Rieter WJ; Bradshaw ML; Gordon LL; Young MA; Keane TE
    World J Urol; 2013 Dec; 31(6):1327-32. PubMed ID: 23595605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy.
    Kimura M; Tsivian M; Mouraviev V; Mayes JM; Price MM; Bannister MC; Madden JF; Wong TZ; Polascik TJ
    Int J Urol; 2009 Dec; 16(12):971-5. PubMed ID: 19843189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
    Raj GV; Partin AW; Polascik TJ
    Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
    Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results.
    Nanni C; Schiavina R; Boschi S; Ambrosini V; Pettinato C; Brunocilla E; Martorana G; Fanti S
    Eur J Nucl Med Mol Imaging; 2013 Jul; 40 Suppl 1():S11-7. PubMed ID: 23591953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer.
    Ellis RJ; Kaminsky DA; Zhou EH; Fu P; Chen WD; Brelin A; Faulhaber PF; Bodner D
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):29-34. PubMed ID: 20961696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 111-In-capromab pendetide imaging using hybrid-γ camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer.
    Tsivian M; Wright T; Price M; Mouraviev V; Madden JF; Kimura M; Wong T; Polascik TJ
    Urol Oncol; 2012; 30(2):150-4. PubMed ID: 20189846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients.
    Nanni C; Schiavina R; Brunocilla E; Borghesi M; Ambrosini V; Zanoni L; Gentile G; Vagnoni V; Romagnoli D; Martorana G; Fanti S
    Clin Genitourin Cancer; 2014 Apr; 12(2):106-10. PubMed ID: 24135632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of
    Gusman M; Aminsharifi JA; Peacock JG; Anderson SB; Clemenshaw MN; Banks KP
    Radiographics; 2019; 39(3):822-841. PubMed ID: 31059396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.
    Nagda SN; Mohideen N; Lo SS; Khan U; Dillehay G; Wagner R; Campbell S; Flanigan R
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):834-40. PubMed ID: 17293236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.
    Beheshti M; Imamovic L; Broinger G; Vali R; Waldenberger P; Stoiber F; Nader M; Gruy B; Janetschek G; Langsteger W
    Radiology; 2010 Mar; 254(3):925-33. PubMed ID: 20177103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in SPECT/CT imaging of prostate cancer.
    Seo Y; Franc BL; Hawkins RA; Wong KH; Hasegawa BH
    Technol Cancer Res Treat; 2006 Aug; 5(4):329-36. PubMed ID: 16866563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capromab Pendetide imaging of prostate cancer.
    Haseman MK; Rosenthal SA; Polascik TJ
    Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.